REXO1

Across TCGA pan-cancer cohorts, REXO1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated REXO1 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher REXO1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated REXO1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where REXO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.866	0.452	.005	49	view →
LSCC	OS	Median	All	0.943	0.792	.003	28	view →
PDAC	OS	Quartile	All	0.246	0.742	.001	27	view →
UCEC	DFS	Median	II,III,IV	1.000	0.587	.035	10	view →
GBM	OS	Median	All	0.908	0.825	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

REXO1–LUAD (DFS)

Open the LUAD breakdown →